NRAS Mutation Analysis
Alternative name:
NRAS Gene Sequencing, NRAS Exons 2-4
Methodology
Molecular
Test Description and clinical significance
Genes
NRAS (Exons 2,3,4)
Disease:
Giant congenital melanocytic nevus, Noonan syndrome, Autoimmune lymphoproliferative syndrome, Cholangiocarcinoma, Core binding factor acute myeloid leukemia, Cytogenetically normal acute myeloid leukemia, Epidermal nevus, Lung cancer, Melanoma, and colon cancer
Molecular test that utilizes NGS technology to detect mutations in NRAS. NRAS (also known as Neuroblastoma-RAS) is a commonly mutated oncogene in human cancer. The majority (97%) of mutations involve codons 12, 13, and 61. NRAS mutational status is useful in guiding therapy in patients with certain cancers including colon cancer and melanoma.
Specimen Requirements
Collection:
FFPE sections, 5-10 sections are recommended at 4 to 10 micron. A minimum of 20 ?l of each DNA with a concentration of at least 5ng/?l and an OD260/280 ratio of 1.7-1.9 and 2.0-2.1 respectively, obtained on a spectrophotometer is required.
Stability:
FFPE blocks- Indefinitely/ FFPE Slides-4 weeks
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Unlabeled or improperly labeled specimens. Decalcified specimens. Improperly stored DNA or RNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Genomic DNA must be stored at 2–8°C for several weeks post extraction, then at –15 to –25°C for long term storage
CPT(s)
81311
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
